{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:22:44Z","timestamp":1792736564326,"version":"4.5.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100017239","name":"Ingrid Asps Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"publisher","award":["R\u00d6-1013485"],"award-info":[{"award-number":["R\u00d6-1013485"]}],"id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"publisher","award":["R\u00d6\u2212981263"],"award-info":[{"award-number":["R\u00d6\u2212981263"]}],"id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Familjerna Carl och Albert Molins i Motala minne Foundation"},{"DOI":"10.13039\/501100008035","name":"Njurfonden","doi-asserted-by":"publisher","award":["F2025-0124"],"award-info":[{"award-number":["F2025-0124"]}],"id":[{"id":"10.13039\/501100008035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["FoUI-977096"],"award-info":[{"award-number":["FoUI-977096"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["FoUI-964139"],"award-info":[{"award-number":["FoUI-964139"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-1013624"],"award-info":[{"award-number":["R-1013624"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R\u2212993724"],"award-info":[{"award-number":["R\u2212993724"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Stiftelsen Konung Gustaf V:s Jubileumsfond","doi-asserted-by":"publisher","award":["FAI-2023-1055"],"award-info":[{"award-number":["FAI-2023-1055"]}],"id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Stiftelsen Konung Gustaf V:s Jubileumsfond","doi-asserted-by":"publisher","award":["FAI\u22122022\u22120877"],"award-info":[{"award-number":["FAI\u22122022\u22120877"]}],"id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1023269"],"award-info":[{"award-number":["OLL-1023269"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009800","name":"Stiftelsen Professor Nanna Svartz Fond","doi-asserted-by":"publisher","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}],"id":[{"id":"10.13039\/501100009800","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024-43"],"award-info":[{"award-number":["2024-43"]}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023\u221202256"],"award-info":[{"award-number":["2023\u221202256"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2023-36"],"award-info":[{"award-number":["2023-36"]}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02360-8","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:35:10Z","timestamp":1784608510000},"page":"1453-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Balancing Act: The Dual Roles of BAFF in Systemic Lupus Erythematosus"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-294X","authenticated-orcid":false,"given":"Jhonatan Antonio","family":"\u00c1lvarez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-5060","authenticated-orcid":false,"given":"Daniel","family":"Appelgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-4866","authenticated-orcid":false,"given":"Tomas","family":"Walhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-2048","authenticated-orcid":false,"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2360_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0427-9","author":"K Kwak","year":"2019","unstructured":"Kwak K, Akkaya M, Pierce SK. B cell signaling in context. Nat Immunol. 2019. https:\/\/doi.org\/10.1038\/s41590-019-0427-9.","journal-title":"Nat Immunol"},{"issue":"3","key":"2360_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri2491","volume":"9","author":"S Herzog","year":"2009","unstructured":"Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009;9(3):195\u2013205. https:\/\/doi.org\/10.1038\/nri2491.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2360_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nri1939","volume":"6","author":"D Nemazee","year":"2006","unstructured":"Nemazee D. Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol. 2006;6(10):728\u201340. https:\/\/doi.org\/10.1038\/nri1939.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2360_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nri.2017.19","volume":"17","author":"D Nemazee","year":"2017","unstructured":"Nemazee D. Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17(5):281\u201394. https:\/\/doi.org\/10.1038\/nri.2017.19.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2360_CR5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202001","volume":"218","author":"TJ Tull","year":"2021","unstructured":"Tull TJ, Pitcher MJ, Guesdon W, et al. Human marginal zone B cell development from early T2 progenitors. J Exp Med. 2021;218(4):e20202001. https:\/\/doi.org\/10.1084\/jem.20202001.","journal-title":"J Exp Med"},{"key":"2360_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.016","author":"JG Cyster","year":"2019","unstructured":"Cyster JG, Allen CDC. B cell responses cell interaction dynamics and decisions. Cell. 2019. https:\/\/doi.org\/10.1016\/j.cell.2019.03.016.","journal-title":"Cell"},{"issue":"7","key":"2360_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri.2017.24","volume":"17","author":"DJ Rawlings","year":"2017","unstructured":"Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17(7):421\u201336. https:\/\/doi.org\/10.1038\/nri.2017.24.","journal-title":"Nat Rev Immunol."},{"issue":"12","key":"2360_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716\u201330. https:\/\/doi.org\/10.1038\/nrrheum.2016.186.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2360_CR9","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","volume":"188","author":"J Leffler","year":"2012","unstructured":"Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188(7):3522\u201331. https:\/\/doi.org\/10.4049\/jimmunol.1102404.","journal-title":"J Immunol"},{"issue":"1","key":"2360_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol Mech Dis. 2019;14(1):369\u201393. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043952.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"11","key":"2360_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0616-6","volume":"18","author":"S Giang","year":"2016","unstructured":"Giang S, La Cava A. Regulatory T cells in SLE biology and use in treatment. Curr Rheumatol Rep. 2016;18(11):67. https:\/\/doi.org\/10.1007\/s11926-016-0616-6.","journal-title":"Curr Rheumatol Rep"},{"key":"2360_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","volume":"43","author":"A Su\u00e1rez-Fueyo","year":"2016","unstructured":"Su\u00e1rez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. Curr Opin Immunol. 2016;43:32\u20138. https:\/\/doi.org\/10.1016\/j.coi.2016.09.001.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"2360_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF) structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2360_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-025-00653-y","volume":"11","author":"I Parodis","year":"2025","unstructured":"Parodis I, Rovin BH, Tektonidou MG, et al. Lupus nephritis. Nat Rev Dis Primer. 2025;11(1):69. https:\/\/doi.org\/10.1038\/s41572-025-00653-y.","journal-title":"Nat Rev Dis Primer"},{"issue":"1","key":"2360_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1744666X.2026.2625964","volume":"22","author":"I Parodis","year":"2026","unstructured":"Parodis I, Nikolopoulos D, Brylid A, Hultgren O, Alarc\u00f3n-Riquelme ME, Sj\u00f6wall C. Old and new autoantibodies in systemic lupus erythematosus. Expert Rev Clin Immunol. 2026;22(1):19\u201329. https:\/\/doi.org\/10.1080\/1744666X.2026.2625964.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2360_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","volume":"188","author":"M Hahne","year":"1998","unstructured":"Hahne M, Kataoka T, Schr\u00f6ter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185\u201390. https:\/\/doi.org\/10.1084\/jem.188.6.1185.","journal-title":"J Exp Med"},{"issue":"11","key":"2360_CR17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","volume":"190","author":"F Mackay","year":"1999","unstructured":"Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for Baff develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697\u2013710. https:\/\/doi.org\/10.1084\/jem.190.11.1697.","journal-title":"J Exp Med"},{"issue":"11","key":"2360_CR18","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747\u201356. https:\/\/doi.org\/10.1084\/jem.189.11.1747.","journal-title":"J Exp Med"},{"issue":"10","key":"2360_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/embo-reports\/kve198","volume":"2","author":"M L\u00f3pez\u2010Fraga","year":"2001","unstructured":"L\u00f3pez\u2010Fraga M, Fern\u00e1ndez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001;2(10):945\u201351. https:\/\/doi.org\/10.1093\/embo-reports\/kve198.","journal-title":"EMBO Rep"},{"issue":"1","key":"2360_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood.V97.1.198","volume":"97","author":"B Nardelli","year":"2001","unstructured":"Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97(1):198\u2013204. https:\/\/doi.org\/10.1182\/blood.V97.1.198.","journal-title":"Blood"},{"issue":"3","key":"2360_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/intimm\/dxh043","volume":"16","author":"B Huard","year":"2004","unstructured":"Huard B, Arlettaz L, Ambrose C, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol. 2004;16(3):467\u201375. https:\/\/doi.org\/10.1093\/intimm\/dxh043.","journal-title":"Int Immunol"},{"issue":"1","key":"2360_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2008.06.005","volume":"44","author":"K Suzuki","year":"2008","unstructured":"Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T. Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. Cytokine. 2008;44(1):44\u20138. https:\/\/doi.org\/10.1016\/j.cyto.2008.06.005.","journal-title":"Cytokine"},{"issue":"3","key":"2360_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0092-8674(02)00631-1","volume":"108","author":"Y Liu","year":"2002","unstructured":"Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell. 2002;108(3):383\u201394. https:\/\/doi.org\/10.1016\/S0092-8674(02)00631-1.","journal-title":"Cell"},{"issue":"7","key":"2360_CR24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1021\/bi051685o","volume":"45","author":"TG Cachero","year":"2006","unstructured":"Cachero TG, Schwartz IM, Qian F, et al. Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry. 2006;45(7):2006\u201313. https:\/\/doi.org\/10.1021\/bi051685o.","journal-title":"Biochemistry"},{"key":"2360_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.009","author":"M Eslami","year":"2021","unstructured":"Eslami M, Schneider P. Function, occurrence and inhibition of different forms of BAFF. Curr Opin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.coi.2021.06.009.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"2360_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","volume":"20","author":"M Thien","year":"2004","unstructured":"Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785\u201398. https:\/\/doi.org\/10.1016\/j.immuni.2004.05.010.","journal-title":"Immunity"},{"issue":"9","key":"2360_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00296-014-3020-4","volume":"34","author":"G Boghdadi","year":"2014","unstructured":"Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int. 2014;34(9):1217\u201323. https:\/\/doi.org\/10.1007\/s00296-014-3020-4.","journal-title":"Rheumatol Int"},{"issue":"5","key":"2360_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/09612033221086123","volume":"31","author":"S Sari","year":"2022","unstructured":"Sari S, Cinar S, Yalcinkaya Y, et al. The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus. 2022;31(5):555\u201364. https:\/\/doi.org\/10.1177\/09612033221086123.","journal-title":"Lupus"},{"key":"2360_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000061","author":"I Parodis","year":"2015","unstructured":"Parodis I, Zickert A, Sundelin B, et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med. 2015. https:\/\/doi.org\/10.1136\/lupus-2014-000061.","journal-title":"Lupus Sci Med"},{"issue":"8","key":"2360_CR30","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/art.37995","volume":"65","author":"MA Petri","year":"2013","unstructured":"Petri MA, van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65(8):2143\u201353. https:\/\/doi.org\/10.1002\/art.37995.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2360_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0961203315604909","volume":"25","author":"DA Roth","year":"2016","unstructured":"Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus associated factors and responses to belimumab. Lupus. 2016;25(4):346\u201354. https:\/\/doi.org\/10.1177\/0961203315604909.","journal-title":"Lupus"},{"issue":"17","key":"2360_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1610528.","journal-title":"N Engl J Med"},{"issue":"22","key":"2360_CR33","doi-asserted-by":"publisher","first-page":"12040","DOI":"10.1093\/nar\/gky866","volume":"46","author":"ML Idda","year":"2018","unstructured":"Idda ML, Lodde V, McClusky WG, et al. Cooperative translational control of polymorphic BAFF by NF90 and miR-15a. Nucleic Acids Res. 2018;46(22):12040\u201351. https:\/\/doi.org\/10.1093\/nar\/gky866.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2360_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1623-4","volume":"20","author":"J Friebus-Kardash","year":"2019","unstructured":"Friebus-Kardash J, Trendelenburg M, Eisenberger U, et al. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol. 2019;20(1):430. https:\/\/doi.org\/10.1186\/s12882-019-1623-4.","journal-title":"BMC Nephrol"},{"key":"2360_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103455","volume":"155","author":"MP Pireddu","year":"2025","unstructured":"Pireddu MP, Rizzo G, Congiu F, et al. Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab a potential biomarker for personalized treatment in systemic lupus erythematosus. J Autoimmun. 2025;155:103455. https:\/\/doi.org\/10.1016\/j.jaut.2025.103455.","journal-title":"J Autoimmun"},{"issue":"3","key":"2360_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/blood-2007-09-110874","volume":"111","author":"C Bossen","year":"2008","unstructured":"Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008;111(3):1004\u201312. https:\/\/doi.org\/10.1182\/blood-2007-09-110874.","journal-title":"Blood"},{"issue":"5","key":"2360_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors structure, function and signaling. Semin Immunol. 2006;18(5):263\u201375. https:\/\/doi.org\/10.1016\/j.smim.2006.04.006.","journal-title":"Semin Immunol"},{"issue":"5","key":"2360_CR38","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1096\/fj.08-124669","volume":"23","author":"FC Kimberley","year":"2009","unstructured":"Kimberley FC, Van Bostelen L, Cameron K, et al. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization andcross-linking. FASEB J. 2009;23(5):1584\u201395. https:\/\/doi.org\/10.1096\/fj.08-124669.","journal-title":"FASEB J"},{"issue":"11","key":"2360_CR39","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","volume":"179","author":"JR Darce","year":"2007","unstructured":"Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation1. J Immunol. 2007;179(11):7276\u201386. https:\/\/doi.org\/10.4049\/jimmunol.179.11.7276.","journal-title":"J Immunol"},{"issue":"1","key":"2360_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD, et al. BCMA Is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91\u20138. https:\/\/doi.org\/10.1084\/jem.20031330.","journal-title":"J Exp Med"},{"issue":"1","key":"2360_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62530-2","volume":"16","author":"SR Menzel","year":"2025","unstructured":"Menzel SR, Roth E, Wittner J, et al. B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells. Nat Commun. 2025;16(1):7106. https:\/\/doi.org\/10.1038\/s41467-025-62530-2.","journal-title":"Nat Commun"},{"issue":"8","key":"2360_CR42","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.4049\/jimmunol.1302062","volume":"192","author":"A Caro-Maldonado","year":"2014","unstructured":"Caro-Maldonado A, Wang R, Nichols AG, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014;192(8):3626\u201336. https:\/\/doi.org\/10.4049\/jimmunol.1302062.","journal-title":"J Immunol"},{"issue":"5","key":"2360_CR43","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2007-03-081232","volume":"111","author":"G Badr","year":"2008","unstructured":"Badr G, Borhis G, Lefevre EA, et al. BAFF enhances chemotaxis of primary human B cells a particular synergy between BAFF and CXCL13 on memory B cells. Blood. 2008;111(5):2744\u201354. https:\/\/doi.org\/10.1182\/blood-2007-03-081232.","journal-title":"Blood"},{"issue":"2","key":"2360_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","volume":"173","author":"LG Ng","year":"2004","unstructured":"Ng LG, Sutherland APR, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells1. J Immunol. 2004;173(2):807\u201317. https:\/\/doi.org\/10.4049\/jimmunol.173.2.807.","journal-title":"J Immunol"},{"issue":"9","key":"2360_CR45","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.4049\/jimmunol.174.9.5537","volume":"174","author":"APR Sutherland","year":"2005","unstructured":"Sutherland APR, Ng LG, Fletcher CA, et al. BAFF augments certain Th1-associated inflammatory responses1. J Immunol. 2005;174(9):5537\u201344. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5537.","journal-title":"J Immunol"},{"issue":"3","key":"2360_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/intimm\/dxz068","volume":"32","author":"Y Baba","year":"2020","unstructured":"Baba Y, Saito Y, Kotetsu Y. Heterogeneous subsets of B-lineage regulatory cells (Breg cells). Int Immunol. 2020;32(3):155\u201362. https:\/\/doi.org\/10.1093\/intimm\/dxz068.","journal-title":"Int Immunol"},{"issue":"7","key":"2360_CR47","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.4049\/jimmunol.0902551","volume":"184","author":"M Yang","year":"2010","unstructured":"Yang M, Sun L, Wang S, et al. Cutting edge novel function of B Cell-activating factor in the induction of IL-10\u2013producing regulatory B cells. J Immunol. 2010;184(7):3321\u20135. https:\/\/doi.org\/10.4049\/jimmunol.0902551.","journal-title":"J Immunol"},{"issue":"1","key":"2360_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41467-017-02683-x","volume":"9","author":"X Meng","year":"2018","unstructured":"Meng X, Gr\u00f6tsch B, Luo Y, et al. Hypoxia-inducible factor-1\u03b1 is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat Commun. 2018;9(1):251. https:\/\/doi.org\/10.1038\/s41467-017-02683-x.","journal-title":"Nat Commun"},{"key":"2360_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/nature12979","author":"P Shen","year":"2014","unstructured":"Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014. https:\/\/doi.org\/10.1038\/nature12979.","journal-title":"Nature"},{"issue":"12","key":"2360_CR50","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.4049\/jimmunol.178.12.7868","volume":"178","author":"JG Evans","year":"2007","unstructured":"Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007;178(12):7868\u201378. https:\/\/doi.org\/10.4049\/jimmunol.178.12.7868.","journal-title":"J Immunol"},{"key":"2360_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.02.004","author":"A Nou\u00ebl","year":"2015","unstructured":"Nou\u00ebl A, Pochard P, Simon Q, et al. B-cells induce regulatory T cells through TGF-\u03b2\/IDO production in a CTLA-4 dependent manner. J Autoimmun. 2015. https:\/\/doi.org\/10.1016\/j.jaut.2015.02.004.","journal-title":"J Autoimmun"},{"issue":"173","key":"2360_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005407","volume":"5","author":"F Flores-Borja","year":"2013","unstructured":"Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5(173):173. https:\/\/doi.org\/10.1126\/scitranslmed.3005407.","journal-title":"Sci Transl Med"},{"key":"2360_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.009","author":"PA Blair","year":"2010","unstructured":"Blair PA, Nore\u00f1a LY, Flores-Borja F, et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010. https:\/\/doi.org\/10.1016\/j.immuni.2009.11.009.","journal-title":"Immunity"},{"issue":"7","key":"2360_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26072998","volume":"26","author":"M Talib","year":"2025","unstructured":"Talib M, Gyebrovszki B, Fodor A, et al. PD-L1+ regulatory B cells from rheumatoid arthritis patients have impaired function in suppressing IFN-\u04af and IL-21 production. Int J Mol Sci. 2025;26(7):2998. https:\/\/doi.org\/10.3390\/ijms26072998.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2360_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2010-07-294249","volume":"117","author":"Y Iwata","year":"2011","unstructured":"Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10\u2013competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):2. https:\/\/doi.org\/10.1182\/blood-2010-07-294249.","journal-title":"Blood"},{"key":"2360_CR56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.793","author":"S Walters","year":"2009","unstructured":"Walters S, Webster KE, Sutherland A, et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol. 2009. https:\/\/doi.org\/10.4049\/jimmunol.182.2.793.","journal-title":"J Immunol"},{"issue":"9","key":"2360_CR57","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.4049\/jimmunol.1900057","volume":"204","author":"W Stohl","year":"2020","unstructured":"Stohl W, Yu N. Promotion of T regulatory cells in mice by B cells and BAFF. J Immunol. 2020;204(9):2416\u201328. https:\/\/doi.org\/10.4049\/jimmunol.1900057.","journal-title":"J Immunol"},{"issue":"12","key":"2360_CR58","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.jid.2017.07.843","volume":"137","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Li J, Zhou N, et al. The unknown aspect of BAFF inducing IL-35 production by a CD5+CD1dhiFc\u03b3RIIbhi regulatory B-cell subset in lupus. J Invest Dermatol. 2017;137(12):2532\u201343. https:\/\/doi.org\/10.1016\/j.jid.2017.07.843.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2360_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292028","volume":"19","author":"A Carvalho-Santos","year":"2024","unstructured":"Carvalho-Santos A, Kuhnert LRB, Hahne M, Vasconcellos R, Carvalho-Pinto CE, Villa-Verde DMS. Anti-inflammatory role of APRIL by modulating regulatory B cells in antigen-induced arthritis. PLoS ONE. 2024;19(5):5. https:\/\/doi.org\/10.1371\/journal.pone.0292028.","journal-title":"PLoS ONE"},{"key":"2360_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01368","volume":"10","author":"CM Fehres","year":"2019","unstructured":"Fehres CM, Van Uden NO, Yeremenko NG, et al. APRIL induces a novel subset of IgA+ regulatory B cells that suppress inflammation via expression of IL-10 and PD-L1. Front Immunol. 2019;10:1368. https:\/\/doi.org\/10.3389\/fimmu.2019.01368.","journal-title":"Front Immunol"},{"key":"2360_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.06.002","author":"C Hua","year":"2016","unstructured":"Hua C, Audo R, Yeremenko N, et al. A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. J Autoimmun. 2016. https:\/\/doi.org\/10.1016\/j.jaut.2016.06.002.","journal-title":"J Autoimmun"},{"key":"2360_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646861","author":"G Den Hartog","year":"2018","unstructured":"Den Hartog G, Van Osch TLJ, Vos M, et al. BAFF augments IgA2 and IL-10 production by TLR7\/8 stimulated total peripheral blood B cells. Eur J Immunol. 2018. https:\/\/doi.org\/10.1002\/eji.201646861.","journal-title":"Eur J Immunol"},{"key":"2360_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01913","author":"LC Lighaam","year":"2018","unstructured":"Lighaam LC, Unger PPA, Vredevoogd DW, et al. In vitro-induced human IL-10+ B cells do not show a subset-defining marker signature and plastically co-express IL-10 with pro-inflammatory cytokines. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01913.","journal-title":"Front Immunol"},{"key":"2360_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110728","author":"MC Glass","year":"2022","unstructured":"Glass MC, Glass DR, Oliveria JP, et al. Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2022.110728.","journal-title":"Cell Rep"},{"issue":"3\u20134","key":"2360_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaut.2011.01.005","volume":"36","author":"S Lemoine","year":"2011","unstructured":"Lemoine S, Morva A, Youinou P, Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011;36(3\u20134):3\u20134. https:\/\/doi.org\/10.1016\/j.jaut.2011.01.005.","journal-title":"J Autoimmun"},{"issue":"3","key":"2360_CR66","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","volume":"44","author":"M Menon","year":"2016","unstructured":"Menon M, Blair PA, Isenberg DA, Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity. 2016;44(3):683\u201397. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.012.","journal-title":"Immunity"},{"issue":"1","key":"2360_CR67","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1038\/s41467-022-30613-z","volume":"13","author":"S Shankar","year":"2022","unstructured":"Shankar S, Stolp J, Juvet SC, et al. Ex vivo-expanded human CD19+TIM-1+ regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1\/STAT3 axis. Nat Commun. 2022;13(1):3121. https:\/\/doi.org\/10.1038\/s41467-022-30613-z.","journal-title":"Nat Commun"},{"key":"2360_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/art.38742","author":"N Gao","year":"2014","unstructured":"Gao N, Dresel J, Eckstein V, et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2014. https:\/\/doi.org\/10.1002\/art.38742.","journal-title":"Arthritis Rheumatol"},{"key":"2360_CR69","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1126346","author":"K Heinemann","year":"2016","unstructured":"Heinemann K, Wilde B, Hoerning A, et al. Decreased IL-10+ regulatory B cells (Bregs) in lupus nephritis patients. Scand J Rheumatol. 2016. https:\/\/doi.org\/10.3109\/03009742.2015.1126346.","journal-title":"Scand J Rheumatol"},{"key":"2360_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970906","author":"S Biswas","year":"2022","unstructured":"Biswas S, Bieber K, Manz RA. IL-10 revisited in systemic lupus erythematosus. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.970906.","journal-title":"Front Immunol"},{"issue":"1","key":"2360_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","volume":"25","author":"S Caielli","year":"2019","unstructured":"Caielli S, Veiga DT, Balasubramanian P, et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med. 2019;25(1):75\u201381. https:\/\/doi.org\/10.1038\/s41591-018-0254-9.","journal-title":"Nat Med"},{"issue":"13","key":"2360_CR72","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1073\/pnas.1917834117","volume":"117","author":"F Facciotti","year":"2020","unstructured":"Facciotti F, Larghi P, Bosotti R, et al. Evidence for a pathogenic role of extrafollicular, IL-10\u2013producing CCR6+B helper T cells in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2020;117(13):7305\u201316. https:\/\/doi.org\/10.1073\/pnas.1917834117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2360_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102247","author":"D McCluskey","year":"2025","unstructured":"McCluskey D, Shipa MRA, Chowdhury K, James JA, Cooney LA, Ehrenstein MR. IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102247.","journal-title":"Cell Rep Med."},{"issue":"9767","key":"2360_CR74","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2.","journal-title":"Lancet"},{"key":"2360_CR75","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","volume":"40","author":"D Ramsk\u00f6ld","year":"2019","unstructured":"Ramsk\u00f6ld D, Parodis I, Lakshmikanth T, et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019;40:517\u201327. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.035.","journal-title":"EBioMedicine"},{"issue":"7","key":"2360_CR76","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328\u201337. https:\/\/doi.org\/10.1002\/art.34400.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2360_CR77","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/keae364","volume":"64","author":"SY Bang","year":"2025","unstructured":"Bang SY, Joh CSY, Itamiya T, et al. Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing. Rheumatology (Oxford). 2025;64(4):2220\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/keae364.","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"2360_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt8199","volume":"11","author":"K Imabayashi","year":"2025","unstructured":"Imabayashi K, Yada Y, Kawata K, et al. Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity. Sci Adv. 2025;11(16):eadt8199. https:\/\/doi.org\/10.1126\/sciadv.adt8199.","journal-title":"Sci Adv"},{"key":"2360_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116123","author":"R Park","year":"2025","unstructured":"Park R, Benet Z, Jing Z, Enright J, Fooksman DR. CD138 and APRIL regulate plasma cell survival, competition, and retention in the bone marrow niche. Cell Rep. 2025. https:\/\/doi.org\/10.1016\/j.celrep.2025.116123.","journal-title":"Cell Rep"},{"issue":"1","key":"2360_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03584-x","volume":"27","author":"X Chen","year":"2025","unstructured":"Chen X, Hu L, Zhu L, et al. Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus. Arthritis Res Ther. 2025;27(1):126. https:\/\/doi.org\/10.1186\/s13075-025-03584-x.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2360_CR81","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","volume":"56","author":"M Dall\u2019Era","year":"2007","unstructured":"Dall\u2019Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142\u201350. https:\/\/doi.org\/10.1002\/art.23047.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2360_CR82","doi-asserted-by":"publisher","first-page":"e2560167","DOI":"10.1001\/jamanetworkopen.2025.60167","volume":"9","author":"S Hundal","year":"2026","unstructured":"Hundal S, Cappelli J, Sj\u00f6wall C, et al. Cost-effectiveness of early vs delayed belimumab treatment for systemic lupus erythematosus. JAMA Netw Open. 2026;9(2):e2560167. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.60167.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2360_CR83","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-018-03323-8","volume":"9","author":"M Vigolo","year":"2018","unstructured":"Vigolo M, Chambers MG, Willen L, et al. A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nat Commun. 2018;9(1):1199. https:\/\/doi.org\/10.1038\/s41467-018-03323-8.","journal-title":"Nat Commun"},{"key":"2360_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005444","author":"I Parodis","year":"2025","unstructured":"Parodis I, Lindblom J, Palazzo L, et al. Outcomes of patients with systemic lupus erythematosus treated with belimumab a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria. RMD Open. 2025. https:\/\/doi.org\/10.1136\/rmdopen-2025-005444.","journal-title":"RMD Open"},{"issue":"2","key":"2360_CR85","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/rheumatology\/kead253","volume":"63","author":"A Gomez","year":"2024","unstructured":"Gomez A, J\u00e4gerback S, Sj\u00f6wall C, Parodis I. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus results from 4 phase III clinical trials. Rheumatology (Oxford). 2024;63(2):338\u201348. https:\/\/doi.org\/10.1093\/rheumatology\/kead253.","journal-title":"Rheumatology (Oxford)"},{"key":"2360_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000412","author":"MB Urowitz","year":"2020","unstructured":"Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy a post hoc longitudinal study. Lupus Sci Med. 2020. https:\/\/doi.org\/10.1136\/lupus-2020-000412.","journal-title":"Lupus Sci Med"},{"issue":"6","key":"2360_CR87","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/rheumatology\/keaf128","volume":"64","author":"A Gomez","year":"2025","unstructured":"Gomez A, Walhelm T, Loeff FC, et al. Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting. Rheumatology (Oxford). 2025;64(6):3797\u2013805. https:\/\/doi.org\/10.1093\/rheumatology\/keaf128.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2360_CR88","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ard.2025.10.010","volume":"85","author":"F Sun","year":"2026","unstructured":"Sun F, Wang H, Zhang D, et al. Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2026;85(3):489\u201396. https:\/\/doi.org\/10.1016\/j.ard.2025.10.010.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2360_CR89","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.ekir.2023.06.021","volume":"8","author":"I Parodis","year":"2023","unstructured":"Parodis I, Lindblom J, Cetrez N, et al. Effect of belimumab on preventing de novo renal lupus flares. Kidney Int Rep. 2023;8(9):1822\u201330. https:\/\/doi.org\/10.1016\/j.ekir.2023.06.021.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"2360_CR90","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2001180.","journal-title":"N Engl J Med"},{"key":"2360_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa796","author":"I Parodis","year":"2021","unstructured":"Parodis I, Vital EM, Hassan SU, et al. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021. https:\/\/doi.org\/10.1093\/rheumatology\/keaa796.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2360_CR92","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/03009742.2014.887769","volume":"43","author":"C Sj\u00f6wall","year":"2014","unstructured":"Sj\u00f6wall C, C\u00f6ster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43(5):428\u201330. https:\/\/doi.org\/10.3109\/03009742.2014.887769.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"2360_CR93","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.semarthrit.2016.09.006","volume":"46","author":"C Staveri","year":"2017","unstructured":"Staveri C, Karokis D, Liossis SNC. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum. 2017;46(6):788\u201390. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.006.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2360_CR94","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/03009742.2019.1603324","volume":"48","author":"C Anjo","year":"2019","unstructured":"Anjo C, Mascar\u00f3 JM Jr, Espinosa G, Cervera R. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol. 2019;48(6):469\u201373. https:\/\/doi.org\/10.1080\/03009742.2019.1603324.","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"2360_CR95","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3899\/jrheum.150470","volume":"42","author":"JS Hui-Yuen","year":"2015","unstructured":"Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288\u201395. https:\/\/doi.org\/10.3899\/jrheum.150470.","journal-title":"J Rheumatol"},{"issue":"10","key":"2360_CR96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms21103463","volume":"21","author":"I Parodis","year":"2020","unstructured":"Parodis I, \u00c5kerstr\u00f6m E, Sj\u00f6wall C, et al. Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Int J Mol Sci. 2020;21(10):10. https:\/\/doi.org\/10.3390\/ijms21103463.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2360_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-025-09673-y","volume":"73","author":"Q Peng","year":"2025","unstructured":"Peng Q, Zhang R, Qiu S, et al. Effects of belimumab on peripheral blood Breg cells and cytokines in childhood systemic lupus erythematosus. Immunol Res. 2025;73(1):116. https:\/\/doi.org\/10.1007\/s12026-025-09673-y.","journal-title":"Immunol Res"},{"issue":"7","key":"2360_CR98","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, Kobayashi T, Mizumaki K, et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv. 2018;4(7):eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944.","journal-title":"Sci Adv"},{"key":"2360_CR99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/JIR.S67751","volume":"7","author":"J Manetta","year":"2014","unstructured":"Manetta J, Bina H, Ryan P, Fox N, Witcher DR, Kikly K. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014;7:121\u201331. https:\/\/doi.org\/10.2147\/JIR.S67751.","journal-title":"J Inflamm Res"},{"issue":"2","key":"2360_CR100","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207653.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2360_CR101","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207654.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2360_CR102","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","volume":"17","author":"W Stohl","year":"2015","unstructured":"Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u201cpeptibody\u201d blisibimod (AMG 623\/A-623) results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17(1):215. https:\/\/doi.org\/10.1186\/s13075-015-0741-z.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2360_CR103","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE) results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213032.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2360_CR104","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/ar2959","volume":"12","author":"SR Dillon","year":"2010","unstructured":"Dillon SR, Harder B, Lewis KB, et al. B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12(2):R48. https:\/\/doi.org\/10.1186\/ar2959.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2360_CR105","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70(2):266\u201376. https:\/\/doi.org\/10.1002\/art.40360.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2360_CR106","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","volume":"59","author":"EF Morand","year":"2020","unstructured":"Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59(10):2930\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keaa029.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2360_CR107","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","volume":"60","author":"DJ Wallace","year":"2021","unstructured":"Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5379\u201389. https:\/\/doi.org\/10.1093\/rheumatology\/keab115.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2360_CR108","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE) 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205067.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2360_CR109","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","volume":"69","author":"C Gordon","year":"2017","unstructured":"Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post hoc analysis of the phase II\/III APRIL-SLE study association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 2017;69(1):122\u201330. https:\/\/doi.org\/10.1002\/art.39809.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2360_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/ar3738","volume":"14","author":"EM Ginzler","year":"2012","unstructured":"Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. https:\/\/doi.org\/10.1186\/ar3738.","journal-title":"Arthritis Res Ther"},{"issue":"14","key":"2360_CR111","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Telitacicept first approval. Drugs. 2021;81(14):1671\u20135. https:\/\/doi.org\/10.1007\/s40265-021-01591-1.","journal-title":"Drugs"},{"issue":"15","key":"2360_CR112","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, et al. A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med. 2025;393(15):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2414719.","journal-title":"N Engl J Med"},{"issue":"9","key":"2360_CR113","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis a single-center, real-world retrospective study. Clin Exp Nephrol. 2024;28(9):902\u20139. https:\/\/doi.org\/10.1007\/s10157-024-02501-x.","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"2360_CR114","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, Demonte D, et al. Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol. 2023;75(7):1187\u2013202. https:\/\/doi.org\/10.1002\/art.42462.","journal-title":"Arthritis Rheumatol"},{"key":"2360_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533093","author":"E Rinaldi","year":"2025","unstructured":"Rinaldi E, Puleo E, Consonni A, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL\/6N mice. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1533093.","journal-title":"Front Immunol"},{"issue":"11","key":"2360_CR116","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70055","volume":"17","author":"R Davies","year":"2024","unstructured":"Davies R, Peng SL, Lickliter J, et al. A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults. Clin Transl Sci. 2024;17(11):e70055. https:\/\/doi.org\/10.1111\/cts.70055.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"2360_CR117","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Posch MG, Li Y, et al. Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214720.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2360_CR118","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ard.2025.11.015","volume":"85","author":"N Agmon-Levin","year":"2026","unstructured":"Agmon-Levin N, Ignatenko S, Gordienko A, et al. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Ann Rheum Dis. 2026;85(3):476\u201388. https:\/\/doi.org\/10.1016\/j.ard.2025.11.015.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2360_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032569","volume":"9","author":"A Jones","year":"2019","unstructured":"Jones A, Muller P, Dore CJ, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9(12):e032569. https:\/\/doi.org\/10.1136\/bmjopen-2019-032569.","journal-title":"BMJ Open"},{"issue":"1","key":"2360_CR120","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121\u201331. https:\/\/doi.org\/10.1002\/art.41466.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2360_CR121","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus. Ann Intern Med. 2021;174(12):1647\u201357. https:\/\/doi.org\/10.7326\/M21-2078.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2360_CR122","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/ard-2024-225686","volume":"83","author":"C Aranow","year":"2024","unstructured":"Aranow C, Allaart CF, Amoura Z, et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Ann Rheum Dis. 2024;83(11):1502\u201312. https:\/\/doi.org\/10.1136\/ard-2024-225686.","journal-title":"Ann Rheum Dis"},{"key":"2360_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103369","volume":"151","author":"V Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, et al. CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun. 2025;151:103369. https:\/\/doi.org\/10.1016\/j.jaut.2025.103369.","journal-title":"J Autoimmun"},{"key":"2360_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/nature11501","author":"A Yoshizaki","year":"2012","unstructured":"Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012. https:\/\/doi.org\/10.1038\/nature11501.","journal-title":"Nature"},{"key":"2360_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088441","author":"X Yang","year":"2014","unstructured":"Yang X, Yang J, Chu Y, et al. T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0088441.","journal-title":"PLoS ONE"},{"issue":"12","key":"2360_CR126","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330. https:\/\/doi.org\/10.1002\/art.30613.","journal-title":"Arthritis Rheum"},{"issue":"14","key":"2360_CR127","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1177\/0961203316650734","volume":"25","author":"BH Rovin","year":"2016","unstructured":"Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus results from two phase 3 randomized, clinical trials. Lupus. 2016;25(14):1597\u2013601. https:\/\/doi.org\/10.1177\/0961203316650734.","journal-title":"Lupus"},{"issue":"6","key":"2360_CR128","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0961203309102803","volume":"18","author":"C Pena-Rossi","year":"2009","unstructured":"Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547\u201355. https:\/\/doi.org\/10.1177\/0961203309102803.","journal-title":"Lupus"},{"issue":"4","key":"2360_CR129","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387. https:\/\/doi.org\/10.1136\/ard-2023-224854.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2360_CR130","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/08923973.2025.2511761","volume":"47","author":"E Zhang","year":"2025","unstructured":"Zhang E, Zhao C, Wang F, Wang L, Li S, Jiang J. Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus. Immunopharmacol Immunotoxicol. 2025;47(5):579\u201389. https:\/\/doi.org\/10.1080\/08923973.2025.2511761.","journal-title":"Immunopharmacol Immunotoxicol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02360-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02360-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02360-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:44Z","timestamp":1788242564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02360-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":130,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02360-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.P. has received research funding and\/or honoraria from Amgen, Argenx, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb (BMS), Elli Lilly, Gilead, GlaxoSmithKline (GSK), Janssen, Novartis, Otsuka, Roche, UCB, and Viatris. C.S. has received speaker\u2019s honoraria from AstraZeneca, Novartis, Fresenius Kabi and BMS; and since April 2024, CS in an employee of BMS. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS and IP conceived the idea for the article. JAAG performed the literature search and drafted the article. IP, CS, DA and TW revised and edited the manuscript. All authors have read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}